Credo Technology Group Holding Ltd vs Eli Lilly And Co — how do they compare? Credo Technology Group Holding Ltd trades at $256.6 (market cap $46.19B), while Eli Lilly And Co trades at $1,213.85 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 23.4× Credo Technology Group Holding Ltd's market cap, and Eli Lilly And Co pays a 0.57% dividend while Credo Technology Group Holding Ltd pays none. Which is the better fit depends on your goals.
| CRDO | LLY | |
|---|---|---|
Market Cap | $46.19B | $1.08T |
Sector | Technology | Health |
52-Week High | $302.52 | $1.24K |
52-Week Low | $87.81 | $639.43 |
Enterprise Value | $44.77B | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
CRDO trades at $249.89, up 8.45% today, with strong technical momentum above key support at $237. The stock shows exceptional fundamental growth with revenue surging from $437M in 2025 to $1.3B projected for 2026, while maintaining robust 35.37% net margins. Recent news highlights Credo's strategic positioning in AI infrastructure through contributions to the Open Compute Project and institutional accumulation.
Outlook remains positive given accelerating AI capex and strong analyst consensus (86.7% buy ratings) with $285.42 price target. Key risks include premium valuation (P/E 95.6), customer concentration, and execution challenges in scaling operations amid competitive AI infrastructure landscape.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →